Zacks Research Boosts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Zacks Research raised their Q1 2026 earnings per share estimates for shares of Globus Medical in a research report issued to clients and investors on Monday, November 4th. Zacks Research analyst R. Department now forecasts that the medical device company will post earnings per share of $0.85 for the quarter, up from their prior forecast of $0.84. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2026 earnings at $1.03 EPS.

A number of other equities analysts have also issued reports on GMED. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a report on Wednesday. Piper Sandler lifted their target price on Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday. BTIG Research upped their price target on Globus Medical from $77.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Truist Financial increased their price target on Globus Medical from $78.00 to $79.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Finally, Stifel Nicolaus boosted their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $87.09.

Globus Medical Stock Performance

Shares of Globus Medical stock opened at $82.70 on Wednesday. The company has a market capitalization of $11.20 billion, a P/E ratio of 275.67, a PEG ratio of 2.06 and a beta of 1.17. Globus Medical has a 1 year low of $43.38 and a 1 year high of $84.87. The company’s fifty day moving average is $71.92 and its two-hundred day moving average is $68.16.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.18. The business had revenue of $625.71 million during the quarter, compared to the consensus estimate of $604.69 million. Globus Medical had a return on equity of 8.70% and a net margin of 1.82%. The company’s revenue was up 63.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.57 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. V Square Quantitative Management LLC acquired a new stake in shares of Globus Medical during the 3rd quarter worth about $27,000. Ashton Thomas Private Wealth LLC acquired a new stake in Globus Medical during the second quarter worth approximately $33,000. Farther Finance Advisors LLC grew its stake in Globus Medical by 230.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after acquiring an additional 385 shares during the period. GAMMA Investing LLC raised its holdings in Globus Medical by 254.5% in the 2nd quarter. GAMMA Investing LLC now owns 631 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 453 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in shares of Globus Medical during the 2nd quarter worth $52,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director David D. Davidar sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the sale, the director now owns 536,275 shares of the company’s stock, valued at $40,242,076. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director David D. Davidar sold 30,000 shares of Globus Medical stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the completion of the transaction, the director now owns 536,275 shares of the company’s stock, valued at $40,242,076. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ann D. Rhoads sold 15,000 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the completion of the sale, the director now owns 42,884 shares in the company, valued at $3,017,318.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.54% of the stock is owned by insiders.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.